Transforming Arrhythmia Therapy
About UsLuxMed is pioneering the first and only platform that integrates real-time optical diagnostics and therapeutic ablation to detect and eliminate invisible gaps during cardiac procedures.
While pulsed field ablation (PFA) is fast and safe, physicians lack real-time insight into lesion durability—leaving gaps undetected and driving recurrence and repeat procedures. LuxMed’s catheter uses optical tissue interrogation to diagnose tissue viability and identify gaps in real time—even when tissue is electrically stunned—while simultaneously enabling targeted therapy to address them during the same procedure. By combining diagnostic insight with therapeutic precision, LuxMed transforms ablation from a blind, open-loop process into a closed-loop system designed to improve outcomes, shorten procedures, and reduce costly repeat interventions. |
|
Technology |
|
A high signal in the green band indicates active viable heart muscle.
A high signal in the yellow band identifies fibrotic / scar tissue. |
LuxMed has developed proprietary optical sensing technology that enables electrophysiologists to assess cardiac tissue composition and metabolic activity in real time during ablation procedures. Originally developed at The George Washington University and supported by over $6 million in NIH SBIR/STTR funding, the technology is grounded in rigorous scientific and translational research.
These optical signals provide immediate insight into tissue contact, viability, and lesion formation—even when tissue is electrically stunned—allowing physicians to identify potential gaps and assess lesion progression during the procedure. The technology is being introduced as a diagnostic catheter platform designed to integrate seamlessly into existing mapping and ablation workflows, while establishing the foundation for direct integration into therapeutic ablation systems. LuxMed is initially commercializing optically enabled radiofrequency (RF) diagnostic catheters, with expansion into pulsed field ablation (PFA) applications. |
Optics Drives Unique Ability to Detect
Gaps in PFA Lesions even in Stunned Tissue
Contact Stability
|
|
Gap Detection. Lesion Progression Catheter-Tissue Contact
Catheter Stability Catheter Movement Tissue Composition
Catheter Stability Catheter Movement Tissue Composition
Progress
Clinically Validated
Optically-Enabled RF Catheter used to Successfully Ablate 11 Patients with Cardiac Arrhythmias including A-Fib |
Extensive Preclinical PFA Data
Core capabilities demonstrated in animal model studies across both RF and PFA applications |
Robust IP Portfolio
61 issued patents 20+ pending |
Published Data
HRS 2019
HRS 2016
|
HRS 2019
|
HRS 2016
HRS 2015
|
Team
|
Omar Amirana, MD, Co-Founder, President, Chief Executive Officer, and Board Director
Omar Amirana brings 25+ years in electrophysiology. He co-founded Cardima and held senior roles at EP Technologies, St. Jude Medical and Oxford Bioscience Partners. He has led global product launches, startup formation, and life sciences investments, and has served on multiple EP company boards. He holds an MD from Eastern Virginia Medical School and a BS in Mechanical Engineering from Tufts. |
|
Terry Ransbury, Co-Founder, Chief Technology Officer, and Board Director
Terry Ransbury is a serial entrepreneur with 35+ years in electrophysiology and cardiac rhythm management. He has developed Class II/III devices, holds 40+ patents, and has participated in 600+ ablation procedures. Previously, he led R&D at InnerPulse and held engineering leadership roles at Ventritex and Biosense Webster. He holds a BS in Biomedical and Electrical Engineering from Duke. |
|
Arun Jaganathan, Co-Founder, Vice President of Strategy & Marketing, and Board Observer
Arun Jaganathan has 20 years of experience across venture investing, corporate strategy and medical device operations. He previously held roles at Allied Minds, Boston Scientific, and Fletcher Spaght / Fletcher Spaght Ventures, and has served as General Manager of multiple device companies. He holds a Master’s in Biotechnology from Columbia and a Bachelor’s from McGill. |
Independent Directors
|
R. John Fletcher, Independent Board Director
Mr. Fletcher has 35+ years in healthcare and is Founder & CEO of Fletcher Spaght. Formerly at BCG, he also served as Chairman of Spectranetics through its $2.2B acquisition by Philips. He serves on multiple boards and was named NACD Director of the Year. He holds an MBA from Southern Illinois University. |
|
Rick Randall, Independent Board Director
Mr. Randall has 40+ years in medical devices, with multiple CEO roles including OMNIlife Science, Innovasive Devices, and Target Therapeutics. He has led commercialization of minimally invasive technologies and currently serves on several boards. He holds a BS from SUNY Buffalo. |
|
Reggie Groves, Independent Board Director
Ms. Groves has 30+ years in the medical device industry, including serving as CEO of REVA Medical and senior leadership roles at Medtronic, where she was Head of AF Solutions within the Cardiac Rhythm and Heart Failure division. She has led global product launches, acquisitions, and clinical programs. She holds a BS in Pharmacy and an MBA from Harvard. |
Clinical & Scientific Contributors
|
Jeremy Ruskin, MD
Dr. Ruskin is Founder and Director Emeritus of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. A leader in electrophysiology, he has authored 450+ publications and trained over 120 fellows. His work focuses on catheter ablation, arrhythmia mechanisms, and cardiac safety. |
|
Jonathan P. Piccini, MD
Dr. Piccini is Professor of Medicine at Duke University and Director of Electrophysiology at the Duke Heart Center. He specializes in atrial fibrillation and complex arrhythmias, with over 600 publications and leadership roles in major cardiology societies. |
|
Timothy Maher, MD
Dr. Maher is a cardiac electrophysiologist at Beth Israel Deaconess Medical Center, where he serves as Director of the EP Lab and Co-Director of the Ventricular Tachycardia Center, and is an Instructor in Medicine at Harvard Medical School. He specializes in complex VT ablation, functional substrate mapping, and advanced imaging integration. He is an investigator on multiple preclinical and clinical studies and presents regularly on emerging EP technologies, including RF and pulsed field ablation. |
|
Andrea Natale, MD
Dr. Natale is a globally recognized electrophysiology leader specializing in catheter ablation for complex atrial fibrillation. He serves as Executive Medical Director at the Texas Cardiac Arrhythmia Institute and has pioneered multiple ablation techniques used worldwide. |
|
Vivek Y. Reddy, MD
Dr. Reddy is Director of Cardiac Arrhythmia Services at Mount Sinai and Professor of Medicine. He is a leading electrophysiologist advancing therapies for atrial fibrillation and ventricular arrhythmias, and leads multiple multinational clinical trials in novel cardiac technologies. |
|
Narine Sarvazyan PhD
Dr. Sarvazyan is a professor at George Washington University with 30+ years in cardiac physiology research. Her work spans arrhythmias, ablation imaging, and tissue engineering. She holds multiple patents, has extensive publications, and has received NIH/NSF funding and major awards. |